ArticleAmerican journal of cancer research2017

Molecular mechanism underlying the pharmacological interactions of the protein kinase C-β inhibitor enzastaurin and erlotinib in non-small cell lung cancer cells.

Nele Van Der Steen et al.PubMed ↗Full text ↗

No numbers read from the abstract.